Neurotech International Limited announced the appointment of Dr. Bonni Goldstein as Chief Medical Advisor USA. Dr. Goldstein will play a pivotal role in supporting the Company's regulatory strategy, clinical advancement and patient advocacy in the United States (US). She is a highly respected physician with more than 25 years of clinical experience including 17 years focused exclusively on cannabinoid-based therapeutics. Dr. Goldstein is internationally recognised as a leading authority in the field and has personally treated thousands of children, including those with autism spectrum disorder, epilepsy, and Rett syndrome, making her one of the foremost experts globally in paediatric cannabinoid medicine. Dr. Goldstein's appointment significantly enhances Neurotech's medical leadership. Her extensive experience in paediatric medicine and cannabinoid therapies, significantly bolsters Neurotech's
strategic capability, particularly as the Company advances NTI164 through clinical development and towards commercialisation (subject to regulatory approval). This High-Profile Appointment Provides Strong Independent Validation of Neurotech's Innovative Cannabinoid-Based Therapy, the Company's Clinical and Regulatory Approach and Highlights the Significant Potential Nti164 Holds in Treating Neurological Conditions, Especially Within Paediatric Populations. Dr. Goldstein's Extensive Network and Recognition in Medical, Regulatory, Advocacy and Caregiver Communities Will Further Enhance the Company's Visibility in the Us Market. Dr. Goldstein's Contributions Extend Well Beyond Clinical Care. She Is A Highly Regarded Author and Thought Leader in Medical Cannabis, with Widely Recognised Books That Have Shaped Both Professional and Public Understanding of the Field and Her Research Has Been Featured in Leading Peer-Reviewed Journals. in Recognition of Her Impact, She Has Received Numerous Accolades, Including Being Named Medical Professional of the Year by Americans for Safe Access in 2017. Dr. Goldstein Remains Actively Involved in Research, Education, and Advocacy Efforts to Advance the Responsible Use of Cannabinoid-Based Therapies.